30076
document
Comparison of increasing doses of olmesartan medoxomil , losartan potassium , and valsartan in patients with essential hypertension . This 12-week , randomized , double-blind , forced-titration study compared the efficacy of 3 angiotensin receptor blockers . Patients received olmesartan medoxomil 20 mg , losartan potassium 50 mg , valsartan 80 mg , or placebo once daily . At week 4 , doses were titrated to 40 , 100 , and 160 mg once daily for olmesartan , losartan , and valsartan , respectively . At week 8 , losartan was increased to 50 mg twice daily and valsartan increased to 320 mg once daily ( olmesartan remained at 40 mg once daily ) . The primary end point was mean change from baseline in seated diastolic blood pressure ( SeDBP ) at week 8 . All 3 medications significantly reduced mean SeDBP from baseline compared with placebo at weeks 4 , 8 , and 12 ( P < .001 ) . At week 8 , olmesartan reduced mean SeDBP more than losartan ( P < .001 ) ; more patients in the olmesartan medoxomil group achieved a blood pressure goal of < 140/90 mm Hg ( P < .001 ) . Olmesartan did not reduce mean SeDBP significantly compared with valsartan , although more patients attained blood pressure goal with olmesartan ( P=.031 ) . At week 12 , all agents lowered blood pressure equivalently .
30077
Intervention_Pharmacological
Patients received olmesartan medoxomil 20 mg , losartan potassium 50 mg , valsartan 80 mg , or placebo once daily . At week 4 , doses were titrated to 40 , 100 , and 160 mg once daily for olmesartan , losartan , and valsartan , respectively .
30078
Intervention_Pharmacological
losartan
30079
Intervention_Pharmacological
valsartan
30080
Intervention_Pharmacological
olmesartan
30081
Intervention_Control
placebo
30082
Outcome_Physical
seated diastolic blood pressure ( SeDBP )
30083
Outcome_Physical
mean SeDBP
30084
Outcome_Physical
SeDBP
30085
Outcome_Physical
blood pressure
30086
Outcome_Physical
mean SeDBP
30087
Outcome_Physical
blood pressure
30088
Outcome_Physical
blood pressure
30089
Participant_Condition
patients with essential hypertension